BridgeBio Pharma Past Earnings Performance
Past criteria checks 0/6
BridgeBio Pharma's earnings have been declining at an average annual rate of -18%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 31.3% per year.
Key information
-18.0%
Earnings growth rate
-7.6%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 31.3% |
Return on equity | n/a |
Net Margin | -246.2% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BridgeBio Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 219 | -538 | 185 | 504 |
31 Dec 23 | 9 | -643 | 151 | 456 |
30 Sep 23 | 9 | -613 | 135 | 416 |
30 Jun 23 | 6 | -573 | 130 | 384 |
31 Mar 23 | 78 | -425 | 131 | 385 |
31 Dec 22 | 78 | -481 | 143 | 399 |
30 Sep 22 | 89 | -491 | 166 | 431 |
30 Jun 22 | 91 | -509 | 181 | 443 |
31 Mar 22 | 71 | -596 | 191 | 436 |
31 Dec 21 | 70 | -563 | 189 | 451 |
30 Sep 21 | 57 | -535 | 172 | 419 |
30 Jun 21 | 63 | -495 | 162 | 407 |
31 Mar 21 | 9 | -520 | 154 | 391 |
31 Dec 20 | 8 | -449 | 146 | 337 |
30 Sep 20 | 22 | -402 | 143 | 304 |
30 Jun 20 | 41 | -346 | 131 | 268 |
31 Mar 20 | 41 | -291 | 110 | 233 |
31 Dec 19 | 41 | -261 | 94 | 210 |
30 Sep 19 | 27 | -226 | 74 | 204 |
30 Jun 19 | 0 | -197 | 61 | 180 |
31 Mar 19 | 0 | -155 | 54 | 151 |
31 Dec 18 | 0 | -131 | 44 | 140 |
Quality Earnings: 2CL is currently unprofitable.
Growing Profit Margin: 2CL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2CL is unprofitable, and losses have increased over the past 5 years at a rate of 18% per year.
Accelerating Growth: Unable to compare 2CL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2CL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.9%).
Return on Equity
High ROE: 2CL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.